Vaccine Technologies and Global Markets

• Publication date: January 2011

Global sales of human and animal vaccines reached approximately $25.2 billion in 2009.  The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.   The global market for human vaccines in 2008 was $18.7 billion and, with a continuing increase in the global market, reached $21.2 billion in 2009.  This market is expected to rise at a compound annual growth rate (CAGR) of 19.6% to reach $...

Global sales of human and animal vaccines reached approximately $25.2 billion in 2009.  The market is expected to rise at a compound annual growth rate (CAGR) of 17.9% to reach $64.2 billion by 2015.  
The global market for human vaccines in 2008 was $18.7 billion and, with a continuing increase in the global market, reached $21.2 billion in 2009.  This market is expected to rise at a compound annual growth rate (CAGR) of 19.6% to reach $58.6 billion by the end of 2015. 
The animal vaccines market grew from approximately $3.8 billion in 2008 to about $4.0 billion in 2009, an increase of about 5.9%. This market is expected to increase at a 5.7% compound annual growth rate (CAGR) between 2010 and 2015 to reach $5.6 billion in 2015.



INTRODUCTION

STUDY OBJECTIVES

BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for human and animal (veterinary) vaccines and related vaccine technologies. The key objective is to present a comprehensive analysis of the current market and its future direction in the human and animal (veterinary) vaccines market with their utilization and employment in preventing and/or treating infectious diseases.

This report explores present and future strategies within the human and animal (veterinary) vaccines market, including attenuated (live) vaccines, inactivated (killed) vaccines, conjugate vaccines, recombinant/recombinant DNA (rDNA) vaccines, subunit vaccines, toxoid vaccines, and combination vaccines. The current state of the market, the setbacks, the innovations, and the future needs of the market are discussed in this report. A general overview of vaccines, and related technologies used currently and in the past are discussed in the report.

A detailed analysis of the vaccine industry structure has been conducted. This includes all seven major categories of vaccines broken down by market share belonging to leading manufacturers and/or suppliers. Revenues for each of the seven categories of vaccines are broken down by region. Sales figures are estimated for the 5–year period from 2010 through 2015.

Applications for human and animal (veterinary) vaccines, as to their prophylactic or therapeutic use are also discussed separately in the report, with emphasis in the meningococcal/pneumococcal vaccines, influenza vaccines, pediatric vaccines, adult/adolescent vaccines, travel vaccines, and others. The report also includes significant patents and their allotments in each vaccine technology category.

REASONS FOR DOING THIS STUDY

This study was conducted to provide vital and detailed information regarding human and animal (veterinary) vaccines. The vaccines industry is experiencing growth due to new products hitting the market as well as a general increase in public awareness and more standardized immunization schedules. This study was conducted to provide detailed market analysis of human and animal (veterinary) vaccines along with the different factors affecting this market. While the vaccines market was affected by the global economic downturn, it retained steady growth and new developments are expected to further influence the market. 

Acquisitions, mergers, and alliances by companies and global organizations are covered in this report. The study also discusses the strengths and weaknesses of each category of vaccines in addition to any new technologies/developments, manufacturer/supplier competition, as well as changing immunization coverage rates. 

INTENDED AUDIENCE

This study contributes to the areas of market growth in preventing some disease types through vaccination from the point of view of manufacturers and users. Clinicians, physicians, the pharmaceutical and biopharmaceutical industries, hospitals and research institutes will find this study to be of interest. 

SCOPE OF THE STUDY

The scope of this study encompasses the vaccine human and animal (veterinary) markets. BCC analyzes each market and its applications by its need for disease type requiring vaccination, regulatory environment, technology involved, market projections, and market share. Technological issues include the latest trends and developments. 

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, and many other sources. Data were collected through interviews and correspondence with various analytical/chemical/pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES

Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of pharmaceuticals. Data were gathered from various industry sources. BCC spoke with officials and physicians within the industry, consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade, and government sources.

ABOUT THE AUTHOR

The study has been carried out by a team of professionals in the biotechnology industry. The project manager is Shalini S. Dewan, who holds a master’s degree in Pharmaceutical Chemistry and has over 14 years of industry experience. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2–naphthyl acetic acid. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies in both India and the U.S. Some of her other reports with BCC are Reagents of Chromatography; Spectroscopy, an Enduring Market; Advanced Drug Delivery Systems: New Developments, New Technologies; Orthopedic Drugs, Implants and Devices; Medical Imaging Reagents and Analysis Equipment; Pharmaceutical Regulatory Industry; The Dynamic Media, Sera and Reagent Market in Biotechnology; Contract Pharmaceutical Manufacturing, Research and Packaging; Chiral Technology: Global Markets; Autacoids and Related Drugs: Technologies and Global Markets; Contraceptives: Technologies and Global Markets; Liver Disease Treatments: The Global Market; Hormone Replacement Therapies and Other Hormone Therapies: Global Markets; Cardiovascular Medicine: Diagnostics, Drugs and Devices; and Cancer Therapies: Technologies and Global Markets. 

The lead consultant for this project was Ms. Taruna Chhabra, who holds a Bachelor’s of Science in Biology and is a member of the National Honor Society for Biological Sciences (BBB). 

Global Drug And Medication Industry

Chapter- 1: INTRODUCTION

CHAPTER ONE: INTRODUCTION 1
STUDY OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 2
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 3
RELATED BCC RESEARCH REPORTS 3
BCC ONLINE SERVICES 4
DISCLAIMER 4

Chapter-2: EXECUTIVE SUMMARY

CHAPTER TWO: EXECUTIVE SUMMARY 5
EXECUTIVE SUMMARY 5
SUMMARY TABLE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, THROUGH 2015 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL REVENUE OF HUMAN AND ANIMAL VACCINES, 2008-2015 ($ MILLIONS) 7

Chapter-3: OVERVIEW

CHAPTER THREE: OVERVIEW 8
WHAT IS A VACCINE? 8
HISTORY OF VACCINES 8
TABLE 1 HISTORY OF VACCINES, 1996-2006 8
TABLE 1 (CONTINUED) 9
TYPES OF VACCINES 9
ATTENUATED (LIVE) VACCINES 9
Applications of Attenuated (Live) Vaccines 10
TABLE 2 APPLICATIONS OF ATTENUATED (LIVE) VACCINES 10
Advantages and Disadvantages of Attenuated (Live) Vaccines 10
TABLE 3 ADVANTAGES AND DISADVANTAGES OF ATTENUATED (LIVE) VACCINES 10
TABLE 3 (CONTINUED) 11
INACTIVATED (KILLED) VACCINES 11
Applications of Inactivated (Killed) Vaccines 11
TABLE 4 APPLICATIONS OF INACTIVATED (KILLED) VACCINES 11
TABLE 4 (CONTINUED) 12
Advantages and Disadvantages of Inactivated (Killed) Vaccines 12
TABLE 5 ADVANTAGES AND DISADVANTAGES OF INACTIVED (KILLED) VACCINES 12
TOXOID VACCINES 12
Applications of Toxoid Vaccines 13
TABLE 6 APPLICATIONS OF TOXOID VACCINES 13
Advantages and Disadvantages of Toxoid Vaccines 13
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES 13
SUBUNIT VACCINES 13
Applications of Subunit Vaccines 14
TABLE 8 APPLICATIONS OF SUBUNIT VACCINES 14
Advantages and Disadvantages of Subunit Vaccines 14
TABLE 9 ADVANTAGES AND DISADVANTAGES OF SUBUNIT VACCINES 14
CONJUGATE VACCINES 15
Applications of Conjugate Vaccines 15
TABLE 10 APPLICATIONS OF CONJUGATE VACCINES 15
Advantages and Disadvantages of Conjugate Vaccines 16
TABLE 11 ADVANTAGES AND DISADVANTAGES OF CONJUGATE VACCINES 16
RECOMBINANT VECTOR VACCINES 16
Applications of Recombinant Vector Vaccines 16
TABLE 12 APPLICATIONS OF RECOMBINANT VECTOR VACCINES 16
Advantages and Disadvantages of Recombinant Vector Vaccines 17
TABLE 13 ADVANTAGES AND DISADVANTAGES OF RECOMBINANT VECTOR VACCINES 17
DNA VACCINES 17
Applications of DNA Vaccines 18
TABLE 14 APPLICATIONS OF DNA VACCINES 18
Advantages and Disadvantages of DNA Vaccines 18
TABLE 15 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES 18
INFECTIOUS DISEASES PREVENTABLE BY VACCINES 18
HUMAN DISEASES 19
Viral Diseases 19
TABLE 16 VACCINE–PREVENTABLE HUMAN VIRAL DISEASES 19
TABLE 16 (CONTINUED) 20
TABLE 16 (CONTINUED) 21
Bacterial Diseases 21
TABLE 17 VACCINE–PREVENTABLE HUMAN BACTERIAL DISEASES 21
TABLE 17 (CONTINUED) 22
TABLE 17 (CONTINUED) 23
ANIMAL DISEASES 23
TABLE 18 VACCINE–PREVENTABLE ANIMAL DISEASES IN COMPANION ANIMALS 24
TABLE 18 (CONTINUED) 25
TABLE 19 VACCINE–PREVENTABLE ANIMAL DISEASES IN LIVESTOCK ANIMALS 25
TABLE 19 (CONTINUED) 26
TABLE 20 LIVESTOCK ANIMAL VACCINES 26
TABLE 20 (CONTINUED) 27
TABLE 20 (CONTINUED) 28
TABLE 20 (CONTINUED) 29
TABLE 20 (CONTINUED) 30
TABLE 20 (CONTINUED) 31
TABLE 20 (CONTINUED) 32
TABLE 20 (CONTINUED) 33
TABLE 20 (CONTINUED) 34

Chapter-4: PREVALENCE

CHAPTER FOUR: PREVALENCE 35
INCIDENCE AND IMMUNIZATION OF HUMAN DISEASES 35
REGIONAL DATA 35
TABLE 21 REPORTED INCIDENCE DATA OF HUMAN DISEASES, BY REGION, 2007-2009 35
TABLE 21 (CONTINUED) 36
TABLE 22 IMMUNIZATION COVERAGE DATA OF HUMAN DISEASES, BY REGION, 2007-2009 (%) 36
TABLE 22 (CONTINUED) 37
GLOBAL DATA 37
TABLE 23 REPORTED CASES OF HUMAN DISEASES, 2007 AND 2008 38
TABLE 24   IMMUNIZATION COVERAGE OF HUMAN DISEASES (%) 38
GLOBAL IMMUNIZATION UPTAKE DATA 38
TABLE 25   UPTAKE OF NEW AND UNDERUSED VACCINES, 2008 39
GLOBAL DEATHS DUE TO VACCINE–PREVENTABLE DISEASES 39
TABLE 26   GLOBAL CHILD DEATHS DUE TO VACCINE–PREVENTABLE DISEASES, 2008 40

Chapter-5: REGULATORY ASPECTS

CHAPTER FIVE: REGULATORY ASPECTS 41
TABLE 27   REVISIONS TO EXISTING VACCINES, 2007-2010 41
TABLE 27 (CONTINUED) 42
TABLE 27 (CONTINUED) 43
TABLE 27 (CONTINUED) 44
TABLE 27 (CONTINUED) 45
TABLE 27 (CONTINUED) 46
TABLE 28 NEW VACCINES IN THE GLOBAL MARKET, 2007-2010 47
TABLE 28 (CONTINUED) 48
TABLE 28 (CONTINUED) 49
TABLE 28 (CONTINUED) 50
TABLE 28 (CONTINUED) 51

Chapter-6: INDUSTRY STRUCTURE

CHAPTER SIX: INDUSTRY STRUCTURE 52
WHO–PREQUALIFIED VACCINE MANUFACTURERS/SUPPLIERS 52
TABLE 29 WORLD HEALTH ORGANIZATION (WHO)–PREQUALIFIED MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES, 2010 52
TABLE 29 (CONTINUED) 53
MANUFACTURERS/SUPPLIERS OF HUMAN VACCINES 53
ATTENUATED (LIVE) VACCINES 53
TABLE 30 LEADING MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES 53
TABLE 30 (CONTINUED) 54
INACTIVATED (KILLED) VACCINES 55
TABLE 31 LEADING MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES 55
CONJUGATE VACCINES 56
TABLE 32 LEADING MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES 56
RECOMBINANT / RECOMBINANT DNA (RDNA) VACCINES 56
TABLE 33 LEADING MANUFACTURERS/SUPPLIERS OF RECOMBINANT/ RECOMBINANT DNA (RDNA) VACCINES 56
TABLE 33 (CONTINUED) 57
SUBUNIT VACCINES 57
TABLE 34 LEADING MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES 57
TOXOID VACCINES 57
TABLE 35 LEADING MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES 57
COMBINATION VACCINES 58
TABLE 36  LEADING MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES 58
MARKET SHARES OF INDUSTRY LEADERS OF HUMAN VACCINES 59
ATTENUATED (LIVE) VACCINES 59
TABLE 37   GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%) 59
FIGURE 1   GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF ATTENUATED (LIVE) VACCINES, 2009 (%) 60
INACTIVATED (KILLED) VACCINES 60
TABLE 38 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%) 61
FIGURE 2 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF INACTIVATED (KILLED) VACCINES, 2009 (%) 61
CONJUGATE VACCINES 62
TABLE 39 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%) 62
FIGURE 3 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF CONJUGATE VACCINES, 2009 (%) 63
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES 63
TABLE 40 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%) 64
FIGURE 4 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2009 (%) 64
SUBUNIT VACCINES 65
TABLE 41 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF SUBUNIT VACCINES, 2009 (%) 65
FIGURE 5 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF SUBUNIT VACCINES, 2009 (%) 65
TOXOID VACCINES 66
TABLE 42 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF TOXOID VACCINES, 2009 (%) 66
FIGURE 6 GLOBAL MARKET SHARES OF MANUFACTURERS/ SUPPLIERS OF TOXOID VACCINES, 2009 (%) 66
COMBINATION VACCINES 67
TABLE 43 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%) 67
FIGURE 7 GLOBAL MARKET SHARES OF MANUFACTURERS/SUPPLIERS OF COMBINATION VACCINES, 2009 (%) 67

Chapter-7: NEW DEVELOPMENTS
CHAPTER SEVEN: NEW DEVELOPMENTS 68
NEW DEVELOPMENTS 68
TABLE 44 NEW DEVELOPMENTS IN THE RESEARCH PIPELINE OF HUMAN VACCINES (AS OF AUGUST 2010) 69
TABLE 44 (CONTINUED) 70
TABLE 44 (CONTINUED) 71
TABLE 44 (CONTINUED) 72
TABLE 44 (CONTINUED) 73
TABLE 44 (CONTINUED) 74
Chapter-8: MARKET ANALYSIS: HUMAN

CHAPTER EIGHT: MARKET ANALYSIS: HUMAN 75
TABLE 45 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, THROUGH 2015 ($ MILLIONS) 75
FIGURE 8 GLOBAL MARKET FOR HUMAN VACCINES BY REGION, 2008-2015 ($ MILLIONS) 76
ATTENUATED (LIVE) VACCINES 76
MARKET OVERVIEW 77
MARKET REVENUE 78
TABLE 46 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION,   THROUGH 2015 ($ MILLIONS) 78
FIGURE 9 GLOBAL MARKET FOR ATTENUATED (LIVE) VACCINES, BY REGION, 2008-2015 ($ MILLIONS) 79
INACTIVATED (KILLED) VACCINES 79
MARKET OVERVIEW 80
MARKET REVENUE 81
TABLE 47 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, THROUGH 2015 ($ MILLIONS) 81
FIGURE 10 GLOBAL MARKET FOR INACTIVATED (KILLED) VACCINES, 2008-2015 ($ MILLIONS) 81
CONJUGATE VACCINES 82
MARKET OVERVIEW 82
MARKET REVENUE 83
TABLE 48 GLOBAL MARKET FOR CONJUGATE VACCINES, THROUGH 2015 ($ MILLIONS) 83
FIGURE 11 GLOBAL MARKET FOR CONJUGATE VACCINES, 2008-2015 ($ MILLIONS) 84
RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES 84
MARKET OVERVIEW 84
MARKET REVENUE 85
TABLE 49 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, THROUGH 2015 ($ MILLIONS) 86
FIGURE 12 GLOBAL MARKET FOR RECOMBINANT/RECOMBINANT DNA (RDNA) VACCINES, 2008-2015 ($ MILLIONS) 86
SUBUNIT VACCINES 87
MARKET OVERVIEW 87
MARKET REVENUE 88
TABLE 50 GLOBAL MARKET FOR SUBUNIT VACCINES, THROUGH 2015 ($ MILLIONS) 88
FIGURE 13 GLOBAL MARKET FOR SUBUNIT VACCINES, 2008-2015 ($ MILLIONS) 89
TOXOID VACCINES 89
MARKET OVERVIEW 90
MARKET REVENUE 91
TABLE 51 GLOBAL MARKET FOR TOXOID VACCINES, THROUGH 2015 ($ MILLIONS) 91
FIGURE 14 GLOBAL MARKET FOR TOXOID VACCINES, 2008-2015 ($ MILLIONS) 91
COMBINATION VACCINES 92
MARKET OVERVIEW 92
MARKET REVENUE 93
TABLE 52 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION THROUGH 2015 ($ MILLIONS) 93
FIGURE 15 GLOBAL MARKET FOR COMBINATION VACCINES, BY REGION, 2008-2015 ($ MILLIONS) 94
MARKET SHARES OF HUMAN VACCINES, BY REGION 94
TABLE 53 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%) 95
FIGURE 16 GLOBAL HUMAN VACCINES MARKET SHARES BY REGION, 2009 (%) 95
MARKET SHARES OF HUMAN VACCINES, BY TYPE 95
TABLE 54 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%) 96
FIGURE 17 GLOBAL HUMAN VACCINES MARKET SHARES BY VACCINE TYPE, 2009 (%) 96

Chapter-9: ANIMAL HEALTH MARKET

CHAPTER NINE: ANIMAL HEALTH MARKET 97
INDUSTRY MANUFACTURERS OF ANIMAL HEALTH PRODUCTS 97
MARKET OVERVIEW 98
MARKET REVENUE 99
TABLE 55 GLOBAL ANIMAL HEALTH REVENUES BY MARKET LEADERS, 2008-2010 ($ MILLIONS) 99
TABLE 56 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%) 99
FIGURE 18 GLOBAL ANIMAL HEALTH MARKET SHARES BY REVENUE, 2009 (%) 100
ANIMAL VACCINES 100
TABLE 57 GLOBAL MARKET FOR ANIMAL VACCINES, THROUGH 2015 ($ MILLIONS) 101
FIGURE 19 GLOBAL MARKET FOR ANIMAL VACCINES, 2008-2015 ($ MILLIONS) 102

Chapter-10: MARKET BY APPLICATIONS – HUMANS

CHAPTER TEN: MARKET BY APPLICATIONS – HUMANS 103
TABLE 58 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON MICROORGANISM 103
TABLE 59 DISEASES AND INFECTIONS WITH DEVELOPED HUMAN VACCINES BASED ON TREATMENT 104
MENINGOCOCCAL/PNEUMOCOCCAL DISEASES 105
MARKET REVENUE 105
TABLE 60 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 106
FIGURE 20 GLOBAL SALES OF HUMAN VACCINES IN MENINGOCOCCAL/ PNEUMOCOCCAL DISEASES MARKET, 2008-2015 ($ MILLIONS) 106
TABLE 61 TOP–SELLING GROUPS OF MENINGOCOCCAL/ PENUMOCOCCAL VACCINES FOR 2009 BY MARKET SHARE (%) 107
INFLUENZA (SEASONAL AND PANDEMIC) DISEASES 107
MARKET REVENUE 108
TABLE 62 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 109
FIGURE 21 GLOBAL SALES OF HUMAN VACCINES IN INFLUENZA DISEASES MARKET, 2008-2015 ($ MILLIONS) 109
TABLE 63 TOP–SELLING GROUPS OF INFLUENZA VACCINES BY MARKET SHARE, 2009 (%) 110
PEDIATRIC/POLIO/PERTUSSIS/HIB DISEASES 110
MARKET REVENUE 111
TABLE 64 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/POLIO’ PERTUSSIS/HIB DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 112
FIGURE 22 GLOBAL SALES OF HUMAN VACCINES IN PEDIATRIC/ POLIO/PERTUSSIS/HIB DISEASES MARKET, 2008-2015 ($ MILLIONS) 112
TABLE 65 TOP–SELLING GROUPS OF PEDIATRIC/POLIO/PERTUSSIS/HIB VACCINES BY MARKET SHARE, 2009 (%) 113
ADULT/ADOLESCENT BOOSTER RELATED DISEASES 113
MARKET REVENUE 113
TABLE 66 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER–RELATED DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 114
FIGURE 23 GLOBAL SALES OF HUMAN VACCINES IN ADULT/ADOLESCENT BOOSTER–RELATED DISEASES MARKET, 2008-2015 ($ MILLIONS) 114
TABLE 67 TOP–SELLING GROUPS OF ADULT/ADOLESCENT BOOSTER–RELATED VACCINES BY MARKET SHARE, 2009 (%) 115
TRAVEL AND OTHER ENDEMIC DISEASES 115
MARKET REVENUE 116
TABLE 68 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 117
FIGURE 24 GLOBAL SALES OF HUMAN VACCINES IN TRAVEL AND OTHER ENDEMIC DISEASES MARKET, 2008- 2015 ($ MILLIONS) 117
TABLE 69 TOP–SELLING GROUPS OF TRAVEL AND OTHER ENDEMIC VACCINES BY MARKET SHARE, 2009 (%) 118
HPV DISEASE 118
MARKET REVENUE 119
TABLE 70 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, THROUGH 2015 ($ MILLIONS) 119
FIGURE 25 GLOBAL SALES OF HUMAN VACCINES IN HPV DISEASE MARKET, 2008-2015 ($ MILLIONS) 120
TABLE 71 TOP–SELLING HPV VACCINES IN THE ORDER OF THEIR SALES, 2009 (%) 120
ROTAVIRUS DISEASE 121
MARKET REVENUE 121
TABLE 72 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, THROUGH 2015 ($ MILLIONS) 121
FIGURE 26 GLOBAL SALES OF HUMAN VACCINES IN ROTAVIRUS DISEASE MARKET, 2008-2015 ($ MILLIONS) 122
TABLE 73 TOP–SELLING ROTAVIRUS VACCINES BY MARKET SHARE, 2009 (%) 122
OTHER DISEASES 123
MARKET REVENUE 124
TABLE 74 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, THROUGH 2015 ($ MILLIONS) 124
FIGURE 27 GLOBAL SALES OF HUMAN VACCINES IN OTHER DISEASES MARKET, 2008-2015 ($ MILLIONS) 125
TABLE 75 TOP–SELLING OTHER VACCINES FOR 2009 BY MARKET SHARE (%) 125
MARKET SHARE OF APPLICATIONS 126
TABLE 76 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%) 126
FIGURE 28 SHARE OF VARIOUS CATEGORIES OF VACCINES IN THE HUMAN VACCINES MARKET, 2009 (%) 127

Chapter-11: PATENT ANALYSIS

CHAPTER ELEVEN: PATENT ANALYSIS 128
TOTAL NUMBER OF PATENTS 128
TABLE 77 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 129
FIGURE 29 NUMBER OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 129
FIGURE 30 PERCENT OF SIGNIFICANT PATENTS, 2006 TO SEPTEMBER 2010 (%) 130
PATENTS BY TYPE AND YEAR 130
TABLE 78 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010 131
FIGURE 31 PATENTS BY TECHNOLOGY, 2006 TO SEPTEMBER 2010 131
PATENTS BY COMPANY 132
INACTIVATED (KILLED) VACCINE TECHNOLOGY 132
TABLE 79 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SPETEMBER 2010 132
FIGURE 32 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 133
ATTENUATED (LIVE) VACCINE TECHNOLOGY 133
TABLE 80 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 134
FIGURE 33 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 135
CONJUGATE VACCINE TECHNOLOGY 135
TABLE 81 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 136
FIGURE 34 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 136
TOXOID VACCINE TECHNOLOGY 137
TABLE 82 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 137
FIGURE 35 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 137
RECOMBINANT/RDNA VACCINE TECHNOLOGY 138
TABLE 83 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 138
TABLE 83 (CONTINUED) 139
FIGURE 36 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 139
SUBUNIT VACCINE TECHNOLOGY 140
TABLE 84 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 140
FIGURE 37 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 140
OTHER/COMBINED VACCINE TECHNOLOGY 141
TABLE 85 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 141
TABLE 85 (CONTINUED) 142
FIGURE 38 NUMBER OF U.S. PATENTS BY COMPANY UTILIZING OTHER/ COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 143
PATENTS BY COUNTRY 143
INACTIVATED (KILLED) VACCINE TECHNOLOGY 143
TABLE 86 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 144
FIGURE 39 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 145
ATTENUATED (LIVE) VACCINE TECHNOLOGY 145
TABLE 87 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 145
TABLE 87 (CONTINUED) 146
FIGURE 40 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006–2010 146
CONJUGATE VACCINE TECHNOLOGY 147
TABLE 88 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 147
FIGURE 41 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 148
TABLE 89 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 148
FIGURE 42 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 149
RECOMBINANT/ DNA/ RDNA VACCINE TECHNOLOGY 149
TABLE 90 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 150
FIGURE 43 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING RECOMBINANT/DNA/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 151
SUBUNIT VACCINE TECHNOLOGY 151
TABLE 91 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 152

FIGURE 44 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 152
OTHER/COMBINED VACCINE TECHNOLOGY 152
TABLE 92 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 153
FIGURE 45 NUMBER OF U.S. PATENTS BY COUNTRY UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 154
TABLE 93 NUMBER OF U.S. PATENTS BY COUNTRY FOR ALL VACCINE TYPES, 2006 TO SEPTEMBER 2010 (%) 154
TABLE 93 (CONTINUED) 155
FIGURE 46   PATENT SHARES BY COUNTRY FOR VACCINES, 2006 TO SEPTEMBER 2010 (%) 156
PATENTS BY ASSIGNEE 157
INACTIVATED (KILLED) VACCINE TECHNOLOGY 157
TABLE 94 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 157
FIGURE 47 PATENTS BY ASSIGNEE UTILIZING INACTIVATED (KILLED) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 157
ATTENUATED (LIVE) VACCINE TECHNOLOGY 158
TABLE 95 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 THROUGH SEPTEMBER 2010 158
FIGURE 48 PATENTS BY ASSIGNEE UTILIZING ATTENUATED (LIVE) VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 158
CONJUGATE VACCINE TECHNOLOGY 159
TABLE 96 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 159
FIGURE 49 PATENTS BY ASSIGNEE UTILIZING CONJUGATE VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 159
TOXOID VACCINE TECHNOLOGY 160
TABLE 97 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 160
FIGURE 50 PATENTS BY ASSIGNEE UTILIZING TOXOID VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 160
RECOMBINANT/RDNA VACCINE TECHNOLOGY 161
TABLE 98 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 161
FIGURE 51 PATENTS BY ASSIGNEE UTILIZING RECOMBINANT/RDNA VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 161
SUBUNIT VACCINE TECHNOLOGY 162
TABLE 99 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 162
FIGURE 52 PATENTS BY ASSIGNEE UTILIZING SUBUNIT VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 162
OTHER/COMBINED VACCINE TECHNOLOGY 163
TABLE 100 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 163
FIGURE 53 PATENTS BY ASSIGNEE UTILIZING OTHER/COMBINED VACCINE TECHNOLOGY, 2006 TO SEPTEMBER 2010 163

Chapter-12: CURRENT SITUATION OF THE GLOBAL VACCINES MARKET

FACTS ABOUT THE GLOBAL VACCINES MARKET 164
FACTORS AFFECTING THE SALES OF VACCINES 165
COMPETITION 165
COST 165
TRENDS 166
IMMUNIZATION FUNDING 166
GLOBAL IMMUNIZATION VISION AND STRATEGY (GIVS) 166
TABLE 101 AIMS OF GIVS 167
TABLE 102 GOALS OF GIVS 167
TABLE 103 STRATEGIES OF GIVS 168
CURRENT SITUATION 168
TABLE 104 GLOBAL FUNDING GAP BY REGION FOR IMMUNIZATION WORK, 2010-2011 ($ MILLIONS) 169
VACCINE PREVENTABLE DISEASES UPDATE 169
CURRENT VACCINE PRIORITIZATION 169
TABLE 105 VACCINE PRIORITIZATION, 2009-2010 170
CURRENT AND FUTURE (PROPOSED) VACCINE MILESTONES 171
TABLE 106 VACCINE MILESTONES 2009-2012 171
INFLUENZA VIRUS VACCINES UPDATE FOR THE 2010 THROUGH 2011 SEASON 172
TABLE 107 INFLUENZA VACCINES FOR THE 2010–2011 SEASON 172

Chapter-13: COMPANY PROFILES

ADVAXIS 173
BAYER ANIMAL HEALTH 173
BUL BIO – NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES LTD. (BB–NCIPD LTD.) 174
BHARAT BIOTECH 174
BIO FARMA 175
BIOLOGICAL E. LIMITED 176
BIO–MANGUINHOS 176
BIOPROPERTIES 177
BOEHRINGER INGELHEIM VETMEDICA, INC. 177
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY 178
CEVA SANTE ANIMALE 179
COLORADO SERUM COMPANY 179
CRUCELL 180
CSL LTD. 180
ELI LILLY & CO. 181
EMERGENT BIOSOLUTIONS 182
FATRO 182
GLAXOSMITHKLINE 183
GREEN CROSS 184
HAFFKINE BIO–PHARMACEUTICAL CORPORATION LTD. 184
INDOVAX 185
INSTITUT PASTEUR DE DAKAR 185
INTERCELL 186
JAPAN BCG LABORATORY 186
KING PHARMACEUTICALS INC. 187
LOHMANN INTERNATIONAL 188
MEDIMMUNE 188
MERCK & CO., INC. 189
NIPPON BIOLOGICALS, INC. 190
NOVARTIS AG 190
PANACEA BIOTEC 191
PFIZER INC. 192
ROMVAC 193
SANOFI–AVENTIS (SANOFI PASTEUR) 193
SERUM INSTITUTE OF INDIA LTD. 194
STATENS SERUM INSTITUT 195
THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY 196
VENTRI BIOLOGICALS 196
ZYDUS CADILA 197

Chapter-14: APPENDIX

APPENDIX I 198
ABBREVIATIONS 198